CU6 12.1% $7.67 clarity pharmaceuticals ltd

CU6 - Media and Industry News, page-546

  1. 2,059 Posts.
    lightbulb Created with Sketch. 359
    if the clinical data is solid, this will cause a jump in SP prior to buyout. Further to that, if there are multiple interested parties, this may increase the SP further prior to buyout.

    the stats of premium to buyouts, while handy, don't give you the whole picture. If the SP jumps on first offer, this isn't considered in the buyout premium. If multiple parties want in, then it's game on.

    https://www.fiercebiotech.com/biotech/how-do-you-get-acquired-by-gilead-forty-seven-explains
 
watchlist Created with Sketch. Add CU6 (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.